PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
Bahram Sharif-AskariLilian AmreinRaquel AloyzLawrence PanasciPublished in: Breast cancer research and treatment (2018)
Our results indicated this approach with PARP3 inhibitors and vinorelbine is unique and promising for breast cancer patients with metastases. This combination could significantly increase the survival of breast cancer patients with metastases.